DA
DARE.US Dare Bioscience Inc
- Market cap
- USD 12.9M
- P/E
- -
- P/B
- 29.40x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is DARE.US undervalued?
Graham numberThe Graham number of Dare Bioscience Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dare Bioscience Inc fundamental analysis
No fundamental analysis for Dare Bioscience Inc yet.
Dare Bioscience Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dare Bioscience Inc
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment…
Full company profileDare Bioscience Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dare Bioscience Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 766K | 0.00 | 0.00 | 0.00 | 0.00 | 10.0M | 10.0M | 2.81M | 9.78K | 1.03M | 680K |
| Gross Profit | 366K | 0.00 | -2.44K | -11.1K | -83.3K | -100K | 10.0M | -18.8M | -14.3M | -1.42M | -1.55M |
| Operating Income | -37.2M | -11.2M | -16.9M | -14.3M | -27.4M | -39.1M | -31.4M | -30.9M | -23.5M | -13.6M | -11.9M |
| EBITDA | -36.8M | -8.45M | -11.7M | -14.3M | -27.4M | -38.7M | -31.4M | -30.7M | -4.01M | -10.4M | -9.25M |
| Net Income | -39.3M | -11.5M | -16.7M | -14.3M | -27.4M | -38.7M | 407M | -30.2M | -4.05M | -13.4M | -12.0M |
| EPS | -30 | -43 | -19 | -11 | -11 | -7.59 | 58 | -4.15 | -0.48 | -0.12 | -0.80 |
| Balance Sheet | |||||||||||
| Total Assets | 37.7M | 14.3M | 7.83M | 7.44M | 7.55M | 55.8M | 43.8M | 21.3M | 22.1M | 32.5M | 22.4M |
| Total Liabilities | 24.6M | 967K | 1.10M | 7.00M | 8.70M | 17.1M | 32.7M | 26.3M | 28.1M | 29.6M | 22.9M |
| Shareholders' Equity | 13.1M | 13.3M | 6.73M | 441K | -1.15M | 38.8M | 11.1M | -5.05M | -6.01M | 2.84M | -560K |
| Cash & Short-term Investments | 35.0M | 7.56M | 6.81M | 4.78M | 4.67M | 51.7M | 34.7M | 10.5M | 15.7M | 24.7M | 12.6M |
| Total Debt | 12.8M | - | - | 800K | 757K | 271K | 489K | 1.40M | 1.30M | 2.66M | 6.76M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -33.5M | -2.54M | -10.3M | -13.3M | -25.2M | -28.8M | -18.1M | -38.9M | 5.39M | -9.89M | -24.6M |
| Capital Expenditure | 535K | 11.8K | 11.8K | 17.6K | 17.6K | 14.5K | 63.1K | 629K | 573K | 385K | 161K |
| Free Cash Flow | -34.1M | -2.54M | -10.3M | -13.3M | -25.3M | -28.8M | -18.2M | -39.5M | 4.82M | -10.3M | -24.8M |
| Ratios | |||||||||||
| ROE | -299.8% | -86.5% | -248.8% | -3,235.7% | - | -99.8% | 3,660.9% | - | - | -471.4% | - |
| ROA | -104.3% | -80.7% | -213.9% | -191.6% | -362.9% | -69.3% | 928.2% | -141.7% | -18.3% | -41.3% | -53.5% |
| Net Profit Margin | -5,131.2% | - | - | - | - | -387.0% | 4,068.0% | -1,074.2% | -41,430.9% | -1,300.7% | -1,759.6% |
| Debt to Equity | 0.98x | - | - | 1.82x | - | 0.01x | 0.04x | - | - | 0.93x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Dare Bioscience Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 6.86M | 2.74 | - |
| 2019 | USD 790M | 608 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:12 on Jul 1, 2024.
Who owns Dare Bioscience Inc
- Insiders 12.90%
- Institutions 13.81%
- Public & others 73.29%
- Shares outstanding 19.7M
- Free float 13.5M
Top funds holding DARE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 471K | 2.40% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 88.2K | 0.45% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 41.1K | 0.21% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 23.4K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 15.3K | 0.08% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 2.98K | 0.02% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 2.94K | 0.01% | 0.00% | Sep 2026 |
Top institutions holding DARE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 641K | 3.26% | +38.63% | Jun 2026 |
| Geode Capital Management, LLC | 140K | 0.71% | -21.22% | Jun 2026 |
| U.S. Bancorp | 121K | 0.61% | +32.34% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 91.3K | 0.46% | +38.42% | Jun 2026 |
| BlackRock Inc | 64.2K | 0.33% | +278.58% | Jun 2026 |
| State Street Corp | 47.4K | 0.24% | +101.64% | Jun 2026 |
| Jane Street Group LLC | 36.1K | 0.18% | 0.00% | Jun 2026 |
| Northern Trust Corp | 34.2K | 0.17% | +121.69% | Jun 2026 |
| HRT FINANCIAL LLC | 22.4K | 0.11% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 15.8K | 0.08% | 0.00% | Jun 2026 |
| LPL Financial Corp | 14.9K | 0.08% | +1.71% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 13.3K | 0.07% | +30.29% | Jun 2026 |
| StoneX Group Inc | 11.2K | 0.06% | 0.00% | Jun 2026 |
| Objectivity Squared LLC | 10.9K | 0.06% | 0.00% | Jun 2026 |
| UBS Group AG | 6.81K | 0.03% | -84.30% | Jun 2026 |
| Vanguard Global Advisers, LLC | 2.94K | 0.01% | 0.00% | Jun 2026 |
| Bay Harbor Wealth Management, LLC | 1.36K | 0.01% | 0.00% | Jun 2026 |
| IFS Advisors, LLC | 950.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 645.00 | 0.00% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 396.00 | 0.00% | 0.00% | Jun 2026 |
Dare Bioscience Inc company profile
- Company name
- Dare Bioscience Inc
- Ticker
- DARE.US
- Exchange
- USA Stocks
- Listed since
- Apr 10, 2014
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 21
- Fiscal year end
- December
- Address
- 3655 Nobel Drive, San Diego, CA, United States, 92122
- Phone
- 858 926 7655
- Website
- darebioscience.com
About Dare Bioscience Inc
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1 and DARE-PTB1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB2 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. It has a strategic collaboration with MyMenopauseRx. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
Dare Bioscience Inc management
5- Ms. Sabrina Martucci JohnsonCEO, President, Principal Financial Officer, Secretary & Director · born 1967
- Ms. MarDee J. Haring-LaytonChief Accounting Officer · born 1976
- Mr. Mark WaltersVice President of Operations · born 1955
- Dr. David Friend Ph.D.Chief Scientific Officer
- Ms. Jennifer KiangVice President of Corporate Affairs & Development